What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?

Sean T. Hehn, Thomas P Miller

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) is the most commonly used chemotherapy regimen in North America for the treatment of advanced-stage Hodgkin's lymphoma. Although 60% to 70% of patients with stages III and IV Hodgkin's lymphoma may be cured with ABVD, many patients relapse or progress despite standard therapy. Two new regimens, BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and Stanford V (vinblastine, doxorubicin, vincristine, bleomycin, mustard, etoposide, and prednisone), have shown short-term (3-5 years) overall survival results of 90% or better. Although the results of pilot studies using these regimens and one randomized trial with BEACOPP look promising, the toxicities are substantial. To evaluate overall benefit, two large intergroup trials are underway comparing ABVD versus BEACOPP (European Organization for Research and Treatment of Cancer 20012) and ABVD versus Stanford V (E2496) in advanced Hodgkin's lymphoma.

Original languageEnglish (US)
Pages (from-to)17-26
Number of pages10
JournalCurrent hematology reports
Volume3
Issue number1
StatePublished - Jan 2004

Fingerprint

Bleomycin
Hodgkin Disease
Doxorubicin
Vinblastine
Vincristine
Etoposide
Prednisone
Procarbazine
Dacarbazine
Mustard Plant
North America
Cyclophosphamide
Therapeutics
Recurrence
Drug Therapy
Survival
Research
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

What is the treatment of choice for advanced-stage Hodgkin's lymphoma : ABVD, Stanford V, or BEACOPP? / Hehn, Sean T.; Miller, Thomas P.

In: Current hematology reports, Vol. 3, No. 1, 01.2004, p. 17-26.

Research output: Contribution to journalArticle

@article{217d9dbeabf94cc59fb6cd9549c1ac6d,
title = "What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?",
abstract = "The combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) is the most commonly used chemotherapy regimen in North America for the treatment of advanced-stage Hodgkin's lymphoma. Although 60{\%} to 70{\%} of patients with stages III and IV Hodgkin's lymphoma may be cured with ABVD, many patients relapse or progress despite standard therapy. Two new regimens, BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and Stanford V (vinblastine, doxorubicin, vincristine, bleomycin, mustard, etoposide, and prednisone), have shown short-term (3-5 years) overall survival results of 90{\%} or better. Although the results of pilot studies using these regimens and one randomized trial with BEACOPP look promising, the toxicities are substantial. To evaluate overall benefit, two large intergroup trials are underway comparing ABVD versus BEACOPP (European Organization for Research and Treatment of Cancer 20012) and ABVD versus Stanford V (E2496) in advanced Hodgkin's lymphoma.",
author = "Hehn, {Sean T.} and Miller, {Thomas P}",
year = "2004",
month = "1",
language = "English (US)",
volume = "3",
pages = "17--26",
journal = "Current hematology reports",
issn = "1540-3408",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - What is the treatment of choice for advanced-stage Hodgkin's lymphoma

T2 - ABVD, Stanford V, or BEACOPP?

AU - Hehn, Sean T.

AU - Miller, Thomas P

PY - 2004/1

Y1 - 2004/1

N2 - The combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) is the most commonly used chemotherapy regimen in North America for the treatment of advanced-stage Hodgkin's lymphoma. Although 60% to 70% of patients with stages III and IV Hodgkin's lymphoma may be cured with ABVD, many patients relapse or progress despite standard therapy. Two new regimens, BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and Stanford V (vinblastine, doxorubicin, vincristine, bleomycin, mustard, etoposide, and prednisone), have shown short-term (3-5 years) overall survival results of 90% or better. Although the results of pilot studies using these regimens and one randomized trial with BEACOPP look promising, the toxicities are substantial. To evaluate overall benefit, two large intergroup trials are underway comparing ABVD versus BEACOPP (European Organization for Research and Treatment of Cancer 20012) and ABVD versus Stanford V (E2496) in advanced Hodgkin's lymphoma.

AB - The combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) is the most commonly used chemotherapy regimen in North America for the treatment of advanced-stage Hodgkin's lymphoma. Although 60% to 70% of patients with stages III and IV Hodgkin's lymphoma may be cured with ABVD, many patients relapse or progress despite standard therapy. Two new regimens, BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and Stanford V (vinblastine, doxorubicin, vincristine, bleomycin, mustard, etoposide, and prednisone), have shown short-term (3-5 years) overall survival results of 90% or better. Although the results of pilot studies using these regimens and one randomized trial with BEACOPP look promising, the toxicities are substantial. To evaluate overall benefit, two large intergroup trials are underway comparing ABVD versus BEACOPP (European Organization for Research and Treatment of Cancer 20012) and ABVD versus Stanford V (E2496) in advanced Hodgkin's lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=2442427573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442427573&partnerID=8YFLogxK

M3 - Article

C2 - 14695845

AN - SCOPUS:2442427573

VL - 3

SP - 17

EP - 26

JO - Current hematology reports

JF - Current hematology reports

SN - 1540-3408

IS - 1

ER -